Physician profile
Mark A Vann
NPI 1194036327
$5,128.67
in general payments reported to CMS, 2019-2025
36 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,143 · 2022: $1,146 · 2023: $853 · 2024: $976 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,008.04 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $561.46 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $519.58 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $519.42 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $327.40 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $303.36 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $225.67 | 2021-2024 | Trelegy Ellipta |
| Lundbeck LLC | $178.00 | 2022-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $155.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.18 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.85 | 2021-2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $97.48 | 2021-2025 | Recorlev |
| Biohaven Pharmaceutical Holding Company LTD. | $96.51 | 2022 | |
| Amgen INC. | $83.93 | 2021-2022 | |
| Angiodynamics, INC. | $83.85 | 2025 | Auryon Laser System 100-120 Vac |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $82.41 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $82.29 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $56.39 | 2021-2022 | |
| Astellas Pharma US INC | $55.57 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.19 | 2021-2022 | |
| Abbott Laboratories | $43.75 | 2021-2024 | Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $43.35 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $41.14 | 2024 | Fanapt |
| Azurity Pharmaceuticals, INC. | $33.87 | 2025 | Triptodur |
| Ars Pharmaceuticals Operations, INC. | $29.54 | 2025 | Neffy |
| Esperion Therapeutics, INC. | $26.21 | 2021 | |
| Antares Pharma, INC. | $23.95 | 2025 | Xyosted |
| Vertex Pharmaceuticals Incorporated | $22.77 | 2025 | |
| Alkermes, INC. | $18.38 | 2023 | Lybalvi |
| Phathom Pharmaceuticals, INC. | $16.94 | 2025 | Voquezna |
| Scilex Pharmaceuticals INC. | $15.90 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $14.59 | 2023 | Seglentis |
| Medtronic, INC. | $14.43 | 2025 | Minimed 780g |
| Amarin Pharma, INC. | $13.33 | 2021 | |
| Phadia US INC. | $12.14 | 2021 | |
| Genentech USA, INC. | $3.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.